ALTERITY THERAPEUTICS-ADR
ATHENASDAQTrading Snapshot
- Day Range
- $4.83 – $4.97
- 52-Week Range
- $2.66 – $5.89
- Volume
- $2.66B
- Avg Volume
- $1.96B
- Shares Outstanding
- 16.9M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $2M
- P/E Ratio
- -6.7
- P/S Ratio
- 31.2x
- EPS (TTM)
- $-43.00
- Dividend Yield
- 0.00%
Why Investors Own ATHE
- ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALTERITY THERAPEUTICS-ADR
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Alterity Therapeutics Secures Key US Patent for Lead Asset
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.